Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-313.27	-158.34	-24.52
Net Income Net Income Growth	-292.2	-148.96	-329.57
Earnings Per Share EPS Growth	-2.25	-7819.98	-
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	1,172	652.73	175.18
Total Debt Total Debt Growth	10.22	10.75	0.51
Net Cash (Debt) Net Cash Growth	1,162	641.98	174.67
Net Cash Growth	-	267.54%	-
Net Cash Per Share Net Cash Per Share Growth	8.96	33703.01	-

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-221.62	-120.21	-184.95
Capital Expenditures CapEx Growth	-2.09	-2.09	-0.39
Free Cash Flow Free Cash Flow Growth	-223.7	-122.3	-185.35
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: May 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error